Literature DB >> 31009943

National Institutes of Health Pathways to Prevention Workshop: Research Gaps for Long-Term Drug Therapies for Osteoporotic Fracture Prevention.

Albert Siu1, Heather Allore2, Darryl Brown3, Susan T Charles4, Matthew Lohman5.   

Abstract

On 30 and 31 October 2018, the National Institutes of Health convened the Pathways to Prevention (P2P) Workshop: Appropriate Use of Drug Therapies for Osteoporotic Fracture Prevention to assess the available evidence on long-term (>3 years) use of drug therapies to prevent osteoporotic fractures and identify research gaps and needs for advancing the field. The workshop was cosponsored by the NIH Office of Disease Prevention (ODP), National Institute of Arthritis and Musculoskeletal and Skin Diseases, and National Institute on Aging. A multidisciplinary working group developed the agenda, and an Evidence-based Practice Center prepared an evidence report through a contract with the Agency for Healthcare Research and Quality to facilitate the discussion. During the 1.5-day workshop, invited experts discussed the body of evidence and attendees had the opportunity to comment during open discussions. After data from the evidence report, expert presentations, and public comments were weighed, an unbiased independent panel prepared a draft report that was posted on the ODP Web site for 5 weeks for public comment. This final report summarizes the panel's findings and recommendations. Current gaps in knowledge are highlighted, and a set of recommendations for new, strengthened research to better inform the long-term use of osteoporotic drug therapies is delineated.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31009943     DOI: 10.7326/M19-0961

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  9 in total

1.  A Lot of Progress, With More to Be Done: A Response to NIH Pathways to Prevention Report "Research Gaps for Long-Term Drug Therapies for Osteoporotic Fracture Prevention".

Authors:  Benjamin Z Leder; Bart L Clarke; Elizabeth Shane; Sundeep Khosla; Douglas P Kiel
Journal:  J Bone Miner Res       Date:  2019-07-25       Impact factor: 6.741

Review 2.  Approaches to Fracture Risk Assessment and Prevention.

Authors:  Sanford Baim; Robert Blank
Journal:  Curr Osteoporos Rep       Date:  2021-02-01       Impact factor: 5.096

3.  Osteoporosis Epidemiology Among Adults With Cerebral Palsy: Findings From Private and Public Administrative Claims Data.

Authors:  Zachary P French; Michelle S Caird; Daniel G Whitney
Journal:  JBMR Plus       Date:  2019-10-07

4.  Cost-effectiveness of sequential daily teriparatide/weekly alendronate compared with alendronate monotherapy for older osteoporotic women with prior vertebral fracture in Japan.

Authors:  Takahiro Mori; Carolyn J Crandall; Tomoko Fujii; David A Ganz
Journal:  Arch Osteoporos       Date:  2021-04-17       Impact factor: 2.617

5.  Mechanism of bisphosphonate-related osteonecrosis of the jaw (BRONJ) revealed by targeted removal of legacy bisphosphonate from jawbone using competing inert hydroxymethylene diphosphonate.

Authors:  Hiroko Okawa; Takeru Kondo; Akishige Hokugo; Philip Cherian; Jesus J Campagna; Nicholas A Lentini; Eric C Sung; Samantha Chiang; Yi-Ling Lin; Frank H Ebetino; Varghese John; Shuting Sun; Charles E McKenna; Ichiro Nishimura
Journal:  Elife       Date:  2022-08-26       Impact factor: 8.713

6.  Osteoporosis treatment gap in a prospective cohort of volunteer women.

Authors:  L Iconaru; C Smeys; F Baleanu; V Kinnard; M Moreau; S Cappelle; M Surquin; M Rubinstein; S Rozenberg; M Paesmans; R Karmali; P Bergmann; J J Body
Journal:  Osteoporos Int       Date:  2020-03-03       Impact factor: 4.507

Review 7.  Mitigating osteonecrosis of the jaw (ONJ) through preventive dental care and understanding of risk factors.

Authors:  Jason T Wan; Douglas M Sheeley; Martha J Somerman; Janice S Lee
Journal:  Bone Res       Date:  2020-03-11       Impact factor: 13.567

Review 8.  How much do we know about the role of osteocytes in different phases of fracture healing? A systematic review.

Authors:  Man Huen Victoria Choy; Ronald Man Yeung Wong; Simon Kwoon Ho Chow; Meng Chen Li; Yu Ning Chim; Tsz Kiu Li; Wing Tung Ho; Jack Chun Yiu Cheng; Wing Ho Cheung
Journal:  J Orthop Translat       Date:  2019-08-08       Impact factor: 5.191

9.  Cost-effectiveness of zoledronic acid compared with sequential denosumab/alendronate for older osteoporotic women in Japan.

Authors:  Takahiro Mori; Carolyn J Crandall; Tomoko Fujii; David A Ganz
Journal:  Arch Osteoporos       Date:  2021-07-15       Impact factor: 2.617

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.